Review
Technology evaluation: TriGem, Titan
Affiliations
- PMID: 12772513
Item in Clipboard
Review
Technology evaluation: TriGem, Titan
Curr Opin Mol Ther.
2003 Apr.
Abstract
Titan (formerly Trilex) is developing TriGem, a monoclonal antibody directed against I17, for the potential treatment of advanced cancers that express the GD2 ganglioside, including melanoma, small-cell lung cancer, neuroblastoma and sarcoma. Phase II trials of TriGem for use in advanced melanoma were ongoing by June 2002. TriGem also has potential for the treatment of psoriasis, for which phase II trials had begun by 1996.
Similar articles
-
Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.Cancer Res. 2005 Jul 15;65(14):6425-34. doi: 10.1158/0008-5472.CAN-05-0300. Cancer Res. 2005. PMID: 16024647
-
The anti-idiotype vaccines for immunotherapy.Curr Opin Mol Ther. 2001 Feb;3(1):63-9. Curr Opin Mol Ther. 2001. PMID: 11249733 Review.
-
Technology evaluation: Onyvax-105, Onyvax.Curr Opin Mol Ther. 2003 Dec;5(6):668-72. Curr Opin Mol Ther. 2003. PMID: 14755894
-
Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody.Curr Opin Investig Drugs. 2003 Jun;4(6):710-5. Curr Opin Investig Drugs. 2003. PMID: 12901230 Review.
-
Technology evaluation: EMD-273063, EMD Lexigen.Curr Opin Mol Ther. 2004 Oct;6(5):559-66. Curr Opin Mol Ther. 2004. PMID: 15537058
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical